Sign Out
Aggrastat is contraindicated in patients who are hypersensitive to any component of the product.
Since inhibition of platelet aggregation increases the risk of bleeding, Aggrastat is contraindicated in patients with active internal bleeding; a history of intracranial hemorrhage, intracranial neoplasm, arteriovenous malformation, or aneurysm; and in patients who developed thrombocytopenia following prior exposure to Aggrastat.
